Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Biricodar is a P-glycoprotein and MRP-1 modulator.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 8-10 weeks | $ 1,820.00 | |
50 mg | 8-10 weeks | $ 2,380.00 | |
100 mg | 8-10 weeks | $ 3,100.00 |
Description | Biricodar is a P-glycoprotein and MRP-1 modulator. |
In vitro | Biricodar shows activity against both P-glycoprotein (Pgp) and MRP-1. It also has activity in increasing drug uptake and retention and reversing drug resistance mediated by wild-type BCRP (BCRPR482). Biricodar also increases the uptake, retention and cytotoxicity in HL60/Adr (MRP-1) and 8226/MR20 cells (BCRP(R482)). And it has little effect in MCF7 AdVP3000 cells (BCRP(R482T))[1]. Biricodar effectively inhibits photoaffinity labeling of P-glycoprotein by [3H]azidopine or [125I]iodoaryl azido-prazosin with EC50 values of 0.75 and 0.55 μM[3]. In 8226/Dox6 cells (Pgp), biricodar increases mitoxantrone and daunorubicin uptake by 55 and 100%, respectively, increases their retention by 100 and 60%, respectively, and increases their cytotoxicity 3.1- and 6.9-fold, respectively. VX-710 is a non-macrocyclic pipecolinate derivative which binds the FK506 receptor protein and it has been shown to restore sensitivity in a range of multidrug-resistant cells, including myeloma, melanoma, carcinoma and leukaemia[2]. |
Synonyms | VX-710 |
Molecular Weight | 603.71 |
Formula | C34H41N3O7 |
CAS No. | 159997-94-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Biricodar 159997-94-1 Others VX710 VX-710 VX 710 inhibitor inhibit